Oral semaglutide: difference between revisions
Diff·revision 7 → 8·09:16, 29 Nov 2024
Difference between revision 7 and revision 8 of Oral semaglutide. 6 lines changed; the page grew by 676 bytes.
| Revision 7 — 14:11, 12 Nov 2024 CRP_Cormac (talk) fix a dangling clause 2,537 bytes ±0 | Revision 8 — 09:16, 29 Nov 2024 CategoryBot (talk) bot: normalise citation format 3,213 bytes +676 | ||
|---|---|---|---|
| 20 | Deviations change exposure severalfold, and between-individual variability is correspondingly larger than for the injected formulation.{{r|buckley2018}} | 20 | Deviations change exposure severalfold, and between-individual variability is correspondingly larger than for the injected formulation.{{r|buckley2018}} |
| 21 | 21 | ||
| + | 22 | == Clinical position == | |
| + | 23 | Approved for type 2 diabetes, oral semaglutide reduces glycated haemoglobin by roughly 1.0–1.4 percentage points at the studied doses, with modest weight reduction — smaller effects than weekly injected semaglutide at its obesity dose.{{r|knudsen2019}} | |
| + | 24 | ||
| + | 25 | Its advantage is route. For someone unwilling or unable to inject, an oral option changes what treatment is available at all, and this is the axis on which it competes rather than on effect size.{{r|drucker2018}} | |
| + | 26 | ||
| 22 | == References == | 27 | == References == |
| 23 | {{reflist}} | 28 | {{reflist}} |
| 24 | <ref name="knudsen2019">Knudsen LB, Lau J. "The discovery and development of liraglutide and semaglutide." ''Frontiers in Endocrinology'' 10:155 (2019). PMID 31031702.</ref> | 29 | <ref name="knudsen2019">Knudsen LB, Lau J. "The discovery and development of liraglutide and semaglutide." ''Frontiers in Endocrinology'' 10:155 (2019). PMID 31031702.</ref> |
| 25 | <ref name="buckley2018">Buckley ST, Bækdal TA, Vegge A, et al. "Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist." ''Science Translational Medicine'' 10(467):eaar7047 (2018). PMID 30429357.</ref> | 30 | <ref name="buckley2018">Buckley ST, Bækdal TA, Vegge A, et al. "Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist." ''Science Translational Medicine'' 10(467):eaar7047 (2018). PMID 30429357.</ref> |
| + | 31 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | |
| 26 | 32 | ||
| 27 | {{DEFAULTSORT:Oral semaglutide}} | 33 | {{DEFAULTSORT:Oral semaglutide}} |